The GLP-1 Website Factory — Part 1
There are questionable marketing claims.
There are wildly exaggerated marketing claims.
And then there is VelvetRx, a telehealth website that apparently operates in a mathematical universe where customer reviews can be duplicated across companies, tens of thousands of patients make precisely the same treatment selections day after day, and prestigious medical institutions can appear to support a business without actually having anything to do with it.
It’s a remarkable achievement in modern healthcare marketing.
Who needs to spend years building a reputation when you can simply display five glowing stars, attach a suspiciously specific number to them, sprinkle in some recognizable corporate logos, and let the internet do the rest?
The company presents itself as an established, trustworthy provider of prescription weight-loss medications.
Its website is packed with reassuring language about medical professionals, rigorous testing, customer satisfaction, and impressive results.
But when we started investigating the actual evidence behind those claims, things became decidedly less impressive.
The problem isn’t that VelvetRx has a slick website.
The problem is that the website appears to be manufacturing the impression of an enormous, highly respected healthcare operation through statistics and credibility signals whose origins are either demonstrably duplicated or conspicuously unexplained.
And the deeper we looked, the more extraordinary the contradictions became.
The 14,532-Review Miracle
Let’s begin with one of VelvetRx’s most conspicuous credibility claims.
At the top of its patient intake page, visitors are greeted by five glowing stars and a wonderfully precise number:
14,532 Reviews.
Not approximately 14,000.
Not thousands of happy customers.
14,532.
That’s an extraordinary amount of customer feedback for a relatively young telehealth business.
Naturally, we wanted to see these reviews.
Where were they collected? Who submitted them? What experiences did they describe? And where could prospective patients independently examine this enormous mountain of glowing feedback?
We couldn’t locate a public collection substantiating the number.
VelvetRx’s public Trustpilot profile, for example, showed only dozens of reviews during our October 2026 investigation.
Now, a company can collect reviews through multiple systems. Trustpilot doesn’t have to contain every review a business has ever received.
But when you’re advertising a five-star reputation supported by precisely 14,532 reviews, providing an identifiable source seems like a fairly modest expectation.
And here’s where this story gets considerably stranger.
We found the identical number on another GLP-1 company’s website.
Then another.
Three Brands. One Magical Review Count.
A separate telehealth business called Rejuve Meds displays the same remarkable figure:
14,532 Reviews.
Its intake page also contains the same five-star header, the same style of medical questionnaire, and much of the same underlying software structure.
Then we examined VivaRX.
Care to guess how many reviews its intake page claims?
14,532.
What an extraordinary coincidence.
Three branded medical-intake experiences, each somehow arriving at precisely the same customer-review total.
Not 14,531.
Not 14,533.
The same number, down to the last digit.
Apparently, the healthcare industry has discovered the world’s first synchronized customer-review phenomenon.
We went beyond the screenshots and examined the delivered HTML.
The VelvetRx and Rejuve intake pages use the same underlying application build. Their 14,532-review widgets are identical, including the surrounding star graphics and presentation.
The number is present directly in the server-delivered HTML.
We did not find a review-source link or individual review records in the widget, nor an obvious review-count field in the supplied page configuration.
That doesn’t establish precisely who originally entered the number or whether it exists in a backend database.
But it does establish that these are matching credibility displays distributed through shared software.
There is another important detail: VivaRX’s intake actually uses Rejuve’s underlying store account, even though VivaRX presents itself under separate branding.
That may explain some of the duplication between those two sites. It does nothing to explain why VelvetRx, operating under a different store account, displays the exact same figure.
At minimum, VelvetRx owes prospective patients a clear explanation of whose reviews it is counting.
If 14,532 genuine reviews exist, identify the independently verifiable collection or produce credible supporting records.
If the number belongs to a shared software provider, explain why VelvetRx presents it as part of its own reputation.
And if it is simply a decorative marketing statistic, stop dressing it up as evidence of customer satisfaction.
Apparently, 34,418 Patients Choose VelvetRx Every Single Day. The Same Ones, Apparently.
The review-count mystery would be troubling enough on its own.
But VelvetRx has another mathematical wonderland waiting farther down its homepage.
Under the heading Doctor Prescribed Weight Loss Treatment, three treatment cards prominently announce how many patients selected each medication “today.”
Here are the figures we documented:
| Treatment | Claimed selections today |
|---|---|
| Semaglutide | 15,786 |
| Tirzepatide | 10,979 |
| Oral GLP-1 | 7,653 |
| Total | 34,418 |
Thirty-four thousand, four hundred and eighteen treatment selections.
Today.
For context, that is a substantial daily volume by almost any measure.
If those figures genuinely represented new patient selections every day, VelvetRx would be describing an astonishingly active business.
And yet there’s a peculiar problem.
The numbers don’t appear to change.
During repeated observations of the VelvetRx homepage across different days, the same three figures remained on display.
Precisely 15,786.
Precisely 10,979.
Precisely 7,653.
Day after day.
Apparently, VelvetRx’s customers are creatures of extraordinary consistency.
Not one additional semaglutide selection.
Not one fewer tirzepatide selection.
Not a single deviation in oral GLP-1 interest.
The statistics might as well have been engraved into the side of a monument.
There are possible technical explanations for a number remaining unchanged: static marketing copy, cached data, historical totals, or an incorrectly implemented statistics component.
But those possibilities raise another question.
Why label the number “today” if it isn’t accurately reporting today’s activity?
The word matters.
A lifetime total and a daily count communicate radically different things.
So does the distinction between someone clicking a button and someone actually receiving medical treatment.
VelvetRx doesn’t explain whether a “selection” means an interested visitor, a questionnaire response, a completed consultation, a prescription, or a paying customer.
There is no public methodology.
No reporting dashboard.
No independent verification.
Just three enormous numbers presented as though a bustling medical enterprise is processing a tidal wave of demand every day.
If the figures are genuine, VelvetRx should have little difficulty explaining how they are calculated.
Otherwise, the presentation looks less like healthcare analytics and more like a social-proof prop that somebody forgot was supposed to change.
Stanford Medicine Has Entered the Chat. Unfortunately for VelvetRx.
Next comes the website’s credibility parade.
Prominently displayed near the top of VelvetRx’s homepage is a horizontal strip featuring recognizable names:
Stanford Medicine. Healthline. Fortune. NBC. The New York Times. Bloomberg. Forbes.
That’s an awfully impressive collection of institutional and media recognition.
A prospective patient could reasonably interpret the display as suggesting VelvetRx has been covered, recognized, partnered with, or endorsed by these organizations.
Which makes one question unavoidable.
What exactly did any of these organizations say about VelvetRx?
Our searches failed to identify corresponding coverage, endorsements, or partnerships explaining the logo display.
And Stanford Medicine provided an especially revealing response.
According to correspondence received following an inquiry about the logo, Stanford indicated that it had no connection whatsoever with VelvetRx and raised concerns that the logo’s use could implicate its trademark rights and have legal consequences.
That is rather different from the impression created by a Stanford Medicine logo prominently displayed on a commercial weight-loss website.
Stanford’s own Name Use Guidelines prohibit actual or implied endorsements of outside companies and restrict third-party use of Stanford marks in promotional materials.
Its published rules are unusually clear about the importance of avoiding representations that suggest an institutional relationship where none exists.
Yet there sits the Stanford Medicine logo, rubbing elbows with Forbes and Bloomberg on a website trying to convince customers to purchase medical treatment.
How convenient.
And what about the other organizations?
Did Bloomberg publish a glowing investigation of VelvetRx?
Did Fortune recognize its medical innovation?
Did The New York Times independently evaluate its programs?
Where are the articles?
Where are the links?
Where is the explanation?
An article about the general benefits of GLP-1 medications would not establish an endorsement of VelvetRx.
Neither would a paid advertisement, a syndicated press release, or a reference to a different company.
Recognition must be earned and accurately described. It cannot simply be implied by arranging prestigious logos into a decorative strip.
The website provides no clear explanation of the relationships represented by these logos.
Stanford’s denial makes that omission especially troubling.
The Raven-Symoné Campaign: Real Celebrity, Bigger Questions
VelvetRx does have one legitimate advertising credential worth acknowledging.
The company launched a campaign featuring actress and television personality Raven-Symoné.
The commercial, titled Raven-Symoné Takes Down the Velvet Rope, was produced by Gassed Agency and received coverage in advertising trade publications in October 2026.
The campaign itself is real.
But VelvetRx’s intake page goes beyond merely featuring a celebrity spokesperson.
Its headline invites visitors to try the same GLP-1 weight-loss medication as Raven-Symoné.
That’s a specific representation about medication use.
Not simply an invitation to buy something promoted by a celebrity.
Not merely an assertion that an entertainer supports greater healthcare access.
The language tells prospective patients that the treatment offered is the same medication associated with Raven-Symoné.
That raises legitimate questions.
What exact medication is being referenced?
Does the statement refer to the same active ingredient or the same finished formulation?
What is the basis for representing her personal treatment experience?
The campaign’s existence does not answer those questions.
Nor does a celebrity appearance substantiate the company’s review counts, patient statistics, clinical outcomes, or institutional relationships.
A famous face may attract attention.
It is not a substitute for evidence.
The Incredible Weight-Loss Testimonials—and the Curious Case of Yvonne, Age Zero
VelvetRx’s homepage is also populated with dramatic before-and-after stories.
The claimed results include:
- Michelle, 43: 118 pounds lost.
- Lauren, 37: 84 pounds lost.
- Yvonne: 96 pounds lost.
- Christine, 45: 92 pounds lost.
- Nicole, 39: 79 pounds lost.
The accompanying images and testimonials are presented as verified customer success stories.
Those are remarkable results.
The company should be able to document them and explain what patients can generally expect from its programs.
Instead, the public presentation leaves substantial questions about how the testimonials were verified and whether the exceptional outcomes are representative.
The FTC’s Health Products Compliance Guidance makes clear that advertisers cannot use extraordinary testimonials to imply typical results without appropriate evidence and disclosure.
And then there’s Yvonne.
In the testimonial itself, Yvonne describes being 55 years old.
But beneath her photograph, the site’s identifying label reads:
“Yvonne, 0.”
Apparently, VelvetRx has developed a weight-loss program so advanced that it can reverse not only obesity but the entire aging process.
A 55-year-old woman reduced to a newborn.
Truly groundbreaking medicine.
Of course, this is probably a content-management error.
An incorrect age label doesn’t establish that Yvonne is fictional.
But it’s another example of astonishingly careless presentation on a website asking consumers to trust its accuracy about medical treatment.
The FAQ section provides a similar glimpse into quality control.
In one captured version, expanding the question about eligibility for GLP-1 treatment produced an answer explaining accepted credit cards and insurance arrangements.
Apparently, the company confused Who is medically eligible? with How would you like to pay?
A reasonable distinction, one would think, for a company selling prescription medications.
FDA-Approved Language and the Compounded-Drug Question
There is a much more consequential issue beneath all this marketing theater.
VelvetRx’s homepage prominently advertises:
“FDA-Approved medication prescribed after a short 2 minute quiz.”
It also offers injections containing semaglutide and tirzepatide, along with oral tablets advertised as containing semaglutide or tirzepatide.
Some GLP-1 medications are FDA-approved for weight management, including certain oral formulations.
But compounded medications are not FDA-approved finished drug products.
And there is no FDA-approved oral tirzepatide formulation.
The distinction is not a technicality.
FDA approval concerns a specific medication and formulation that has undergone the agency’s review process.
A compounded preparation does not inherit that approval merely because it contains an ingredient also used in an approved drug.
In March 2026, the FDA announced warning letters to 30 telehealth companies over misleading marketing of compounded GLP-1 products.
The agency specifically criticized advertising that could make consumers believe compounded medicines had the same regulatory approval as commercial products.
Compounding can be lawful under specific circumstances, including qualifying patient-specific prescriptions. But it is not a blanket exemption from federal drug laws, and the end of the semaglutide and tirzepatide shortages has restricted the routine compounding of copies of commercially available medicines.
VelvetRx therefore has some important questions to answer.
Which of its advertised medications are FDA-approved branded products?
Which are compounded preparations?
What is the exact formulation of its oral tirzepatide offering?
Which pharmacy prepares it?
What clinical evidence supports its effectiveness?
And how does the company ensure patients understand those distinctions before purchasing?
A reassuring headline about FDA approval should not leave customers guessing whether the medication they actually receive has ever been evaluated and approved by the FDA.
A prescription questionnaire is not a regulatory approval process.
Neither is a colorful website.
And neither is a marketing agency with a talent for selling things.
We’ll examine VelvetRx’s medication offerings, compounding arrangements, and the relevant FDA requirements in a separate investigation.
Meet the Marketing Men Behind VelvetRx
So who is operating this extraordinary collection of medical marketing claims?
VelvetRx’s terms identify Rocket Health Inc. as the business behind the platform.
California corporate records identify Dean Rojas as CEO and director, with Michael Woolsey serving as CFO and secretary.
Those names become particularly interesting when you examine another company.
Rojas and Woolsey are also co-founders of Gassed Agency, a performance-marketing business specializing in creating and distributing advertising designed to acquire customers.
Gassed has genuine experience working with recognizable brands.
Its founders previously worked at Dr. Squatch, and the agency has been discussed in advertising-industry publications.
But the founders’ experience in direct-response marketing raises questions about their responsibilities at VelvetRx.
We’re not dealing with an obscure medical storefront that accidentally hired an unrelated advertising contractor.
The individuals behind the marketing agency also occupy senior executive positions in the company operating VelvetRx.
That doesn’t establish that they personally created every statistic, wrote every testimonial, or selected every credibility logo.
But it certainly makes them appropriate people to ask about those decisions.
Who approved the 14,532-review claim?
Who determined that the company could advertise 34,418 daily treatment selections?
Who authorized the appearance of Stanford Medicine’s logo?
Who verified the patient testimonials and celebrity medication claims?
And who is responsible for ensuring the distinction between FDA-approved and compounded medications is accurately communicated?
These are not complicated philosophical questions.
They are ordinary questions about management accountability at a company marketing prescription medical treatment.
One would hope that executives experienced in sophisticated digital advertising understand the importance of substantiating advertising claims.
Particularly when the product is not soap, novelty merchandise, or some other comparatively low-risk consumer purchase.
It’s medication.
The Software Behind the Curtain
Our investigation also uncovered something that explains why VelvetRx’s review count appears elsewhere.
VelvetRx’s patient intake runs on a white-label telehealth software platform operated by Rimo Health.
The same platform powers the relevant Rejuve Meds and VivaRX intake experiences.
We verified the connection through the websites’ underlying software and DNS configurations.
All three intake domains route through Rimo’s infrastructure.
Rimo advertises a comprehensive platform for businesses that want to launch their own telehealth brands.
Its services include patient intake, clinician-network coordination, prescription routing, pharmacy integrations, subscription billing, and assistance obtaining healthcare-merchant certification.
In other words, much of the operational machinery behind a medical storefront can be supplied by a third party.
That is not inherently improper. White-label software is commonplace across legitimate industries.
But it raises an especially interesting question when multiple businesses using the same platform present precisely the same five-star review count.
Is the 14,532 figure a standard template value? A merchant-configured statistic? Or an actual pool of reviews that somehow applies to multiple brands?
Our source-code examination established the duplication, but not who originally supplied the figure.
That question belongs to both VelvetRx and the software provider.
The platform connection is sufficiently substantial to warrant its own investigation, particularly because Rimo has also been the subject of reporting about telehealth compliance.
We’ll be examining that infrastructure, the businesses using it, and the people responsible for operating it in subsequent installments.
And Somehow, VelvetRx Is LegitScript Certified
One final detail makes this entire situation considerably more remarkable.
VelvetRx holds LegitScript healthcare certification.
LegitScript is a private certification business whose approval is recognized by major digital advertising platforms.
Its standards address legal compliance, business transparency, prescription practices, and accurate advertising.
Certification can help businesses obtain permission to advertise healthcare products and services through platforms that otherwise restrict such advertising.
In theory, those standards provide an additional layer of scrutiny.
Which makes VelvetRx’s published claims particularly interesting.
We have a certified healthcare website displaying an identical review figure found on other businesses’ intake pages.
It publishes extraordinary daily patient statistics that have remained unchanged during repeated observations.
It displays Stanford Medicine’s logo despite Stanford denying any connection.
And it advertises medications in ways that raise legitimate questions about how FDA approval and compounded formulations are distinguished.
Those issues appear directly relevant to the transparency and advertising standards LegitScript says it enforces.
There are reasonable questions about what the certification review actually covered.
Did LegitScript examine VelvetRx’s review totals?
Did it verify the Stanford Medicine relationship?
Were the claimed daily patient counts reviewed?
Did its analysts examine the oral GLP-1 offerings and the language used to advertise FDA approval?
And if these claims appeared after certification was granted, what ongoing monitoring was performed?
Certification does not necessarily mean that every advertising statement has been independently audited. Nor does the existence of questionable claims prove that LegitScript skipped its entire review process.
But consumers are entitled to ask what protections the certification actually provides.
The problem becomes more interesting because LegitScript has a documented commercial relationship with Rimo, the platform behind VelvetRx’s intake system.
And a September 2026 CBS News investigation independently identified major compliance problems involving certified businesses marketing experimental weight-loss drugs, including questionnaires hosted by Rimo.
That history deserves its own examination.
We will be taking a much closer look at LegitScript’s certification standards, commercial relationships, and actual oversight in a forthcoming article.
VelvetRx Has Some Explaining to Do
For all the scientific language, celebrity promotion, reassuring graphics, and impressive numerical claims, VelvetRx faces a collection of remarkably simple questions.
Where are the 14,532 reviews?
Why do other branded medical websites display the identical number?
How are the 34,418 daily treatment selections calculated?
Why do those figures remain unchanged across repeated observations?
Why does VelvetRx display Stanford Medicine’s logo when Stanford says it has no connection to the company?
What specific relationships explain the other recognizable media and institutional logos?
What records substantiate the exceptional customer weight-loss testimonials?
Which advertised medications are FDA-approved finished products, and which are compounded alternatives?
And who within Rocket Health reviewed and approved these representations?
A transparent company should be able to answer those questions without extraordinary difficulty.
It should not require a forensic examination of website source code to determine why supposedly independent medical businesses are displaying exactly the same customer-review total.
It should not require contacting a prestigious university to discover whether an implied institutional relationship actually exists.
And it should not require monitoring a website for days to question whether the enormous daily patient statistics are genuinely daily.
Yet here we are.
A Beautiful Website Isn’t a Medical Credential
VelvetRx’s marketing creates the impression of an established healthcare business surrounded by happy customers, respected institutions, exceptional medical results, and enormous daily demand.
That’s a persuasive image.
It’s also an image that deserves to be tested against reality.
Our investigation found identical review claims across multiple branded sites, daily statistics that remained unchanged during repeated observations, an unexplained collection of prestigious logos, a direct denial of affiliation from Stanford, and important unanswered questions about medical advertising.
We have not established that every customer review is fabricated, that every patient testimonial is false, or that the company has unlawfully dispensed medication.
Those conclusions require evidence beyond what the public website reveals.
But we have documented enough to challenge the credibility of the presentation itself.
If VelvetRx has more than 14,000 genuine customer reviews, it should be able to substantiate them.
If more than 34,000 patients are selecting treatments every day, it should be able to document what those numbers mean.
And if prestigious institutions are being displayed to establish credibility, the company should be able to explain the relationships represented.
None of that is an unreasonable burden.
It’s the minimum one might expect from a business asking people to trust it with their health.
The problem with manufactured credibility is that eventually someone starts checking the manufacturing process.
And in VelvetRx’s case, that process leads well beyond one website.
It leads to a network of similarly constructed telehealth storefronts, shared patient-intake infrastructure, copied credibility displays, commercial certification services, and the individuals and businesses making money from the system.
VelvetRx is where this investigation began.
It is certainly not where it ends.
About This Investigation
This article is Part 1 of our investigative series, The GLP-1 Website Factory.
Our reporting examined publicly accessible website content, delivered HTML, shared software components, domain configurations, corporate records, advertising materials, and information concerning healthcare advertising and regulatory compliance.
The review totals and daily treatment figures described above were observed in September-October 2026. The Stanford finding reflects correspondence received in response to an inquiry about the company’s use of Stanford Medicine branding.
The identified businesses and individuals may provide additional information that changes or clarifies these findings. We welcome verifiable documentation, corrections, and responses to the questions raised.
Sources and References
- VelvetRx — Official Website
- VelvetRx — GLP-1 Patient Intake
- VelvetRx — Trustpilot Profile
- Rejuve Meds — GLP-1 Patient Intake
- VivaRX — GLP-1 Patient Intake
- Stanford University — Name Use Guidelines
- Federal Trade Commission — Health Products Compliance Guidance
- FDA — Concerns About Unapproved GLP-1 Drugs
- FDA — March 2026 Telehealth GLP-1 Advertising Warning
- Rimo Health — White-Label Telehealth Platform
- LegitScript — Healthcare Certification Standards
- CBS News — A Trusted Seal Made These Websites Look Legit. The Weight-Loss Drug They Sold Wasn’t (September 16, 2026)
- LegitScript — Archived Rimo Health Customer Spotlight
